Processa Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing Next Generation Cancer therapies, has announced a strategic expansion aimed at enhancing its financial flexibility and capital base. The company has secured a strategic investment and is actively exploring the integration of blockchain-based assets into its corporate treasury strategies. This move is part of Processa's broader objective to leverage emerging financial technologies, including select cryptocurrencies, to potentially reduce shareholder dilution and diversify funding sources. The company has engaged LifeSci Capital, LLC for advisory support in implementing this cryptocurrency strategy, aligning with its commitment to long-term value creation and responsible investment stewardship.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.